Beta Drugs Limited has announced its board meeting outcome held on May 25, 2026, wherein it approved the allotment of 6,65,314 equity shares of ₹10 each following the conversion of compulsory convertible debentures issued on November 27, 2024, to Healthquad Trust II and Inti Capital VCC – Inti Capital I at a 1:1 ratio. The company also recently declared its financial results for the quarter ended March 31, 2026, reporting a consolidated net profit of ₹9.05 crore. Revenue for this quarter reached ₹96.86 crore, showing an 8.13% growth compared to the previous quarter. On a year-on-year basis, the revenue saw a marginal decline of 0.9%, while net profit recorded a slight increase of 0.22% compared to the corresponding quarter of the previous year.

Beta Drugs Limited, incorporated in 2005 and headquartered in Panchkula, Haryana, is a pharmaceutical company specializing in oncology and dermatology. The company manufactures and sells a comprehensive portfolio of anti-cancer products, including tablets, capsules, and lyophilized injections. Managed by Mr. Rahul Batra and Mr. Varun Batra, the company is listed on the National Stock Exchange and has expanded its footprint through subsidiaries and strategic acquisitions, such as the 2019 purchase of ADL for backward integration into active pharmaceutical ingredients (APIs). Known for its focus on niche oncology therapy, the company continues to prioritize research and development to deliver innovative healthcare solutions. Ashish Kacholia is a notable investor in the company.